

claims 10-13 correspond to the above compound, a pharmaceutical composition comprising the compound and a method of using the compound.

Applicants also take this opportunity to correct printing errors made by the Patent Office. On the cover page of the patent, two corrections have been made. Both of these corrections were necessitated by printing errors. First, the name of the assignee was incorrectly printed as "Schering-Plough". As can be seen from the original assignment papers filed in the 08/617,751 application, the assignee of record is "Schering Corporation".

Second, the entry under the heading "Related U.S. Application Data" has been corrected to correspond with the information originally provided by the applicants. Apparently, the Patent and Trademark Office inadvertently identified the application as a "continuation-in-part" application of the PCT filing when in fact, this application is the national phase filing of the PCT application. Therefore, the application data has been corrected to recite that it is a "35 U.S.C. §371 application" of the PCT case.

Several other printing errors occurred which are being corrected in the instant reissue application. All of these changes may be found in the original specification. Several of the errors occurred when superscripts or subscripts were incorrectly printed. Some of the errors were simple spelling errors on the part of the USPTO. On column 15, line 13; a word was omitted from the issued patent; i.e., "in a suitable e.g." has been corrected to read "in a suitable solvent, e.g.". Support for this correction can be found on page 17, lines 8-9. In column 16, a large insert of text was omitted during printing, beginning with "variables are ..." and ending with "to obtain a compound XXIII". This insert corrects a large printing error which deleted all of this text from the issued patent. The original text of the specification contains this missing material, as can be seen on page 18, lines 5-27 of the 08/617,751 application. In addition,

several other minor printing error have been corrected. All of these changes to the specification have been made to correct printing errors and do not add any new subject matter to the instant application..

In the claims, claim 8 has been amended to correct one printing error in line 1 of that claim which omitted the term “or” between “treatment” and “prevention”, and one typographical error which corrects the spelling of “atherosclerosis”. The “or” term can be seen in original claim 8, on page 35, line 36. These corrections do not raise any new issues nor do they add new subject matter.

Allowance of the pending claims is respectfully requested. Early and favorable action by the Examiner is earnestly solicited.

AUTHORIZATION

No additional fee is believed to be necessary.

The Commissioner is authorized to charge any additional fees which may be required for this amendment, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2976-4032.

In the event that an extension of time is required, or which may be required in addition to that requested in a petition and for an extension of time, the Commissioner is


requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. 13-4500, Order No. 2976-4032. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: June 15, 2000

By:


Dorothy R. Anth
Reg. No. 36,484

MAILING ADDRESS:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 (Facsimile)